Q3 Earnings Estimate for Bruker Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its earnings estimates for Bruker Corporation, now predicting Q3 2025 EPS of $0.33, a decrease from the previous estimate of $0.64.
• Bruker's recent quarterly earnings report indicated $0.32 EPS, falling short of the analysts' consensus estimate of $0.33, and revenue decreased by 0.4% year-over-year.
• Multiple analysts have lowered their price targets for Bruker, with Goldman Sachs and UBS Group setting targets at $45.00, indicating a bearish outlook on the stock.

Bruker Corporation (NASDAQ:BRKR - Free Report) - Equities researchers at Leerink Partnrs dropped their Q3 2025 earnings estimates for shares of Bruker in a note issued to investors on Monday, August 4th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $0.33 for the quarter, down from their previous forecast of $0.64. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker's FY2025 earnings at $2.01 EPS and Q2 2026 earnings at $0.51 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%. The business's quarterly revenue was down .4% on a year-over-year basis. During the same quarter last year, the business posted $0.52 earnings per share.

BRKR has been the topic of a number of other reports. The Goldman Sachs Group lowered their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Barclays reduced their price objective on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Monday, August 4th. UBS Group reduced their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Bank of America cut their price target on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Finally, Wells Fargo & Company cut their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $51.30.

Bruker Stock Down 0.5%

Shares of NASDAQ BRKR traded down $0.14 during midday trading on Thursday, reaching $30.29. The company's stock had a trading volume of 1,926,735 shares, compared to its average volume of 2,449,479. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. Bruker has a fifty-two week low of $30.00 and a fifty-two week high of $72.94. The stock has a market capitalization of $4.60 billion, a price-to-earnings ratio of 58.21, a PEG ratio of 2.52 and a beta of 1.16. The stock has a 50 day simple moving average of $39.45 and a 200-day simple moving average of $42.42.

Institutional Trading of Bruker

Institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its holdings in shares of Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock worth $25,000 after buying an additional 487 shares in the last quarter. Pinnacle Bancorp Inc. bought a new position in shares of Bruker in the 1st quarter worth $29,000. Allworth Financial LP lifted its position in shares of Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after purchasing an additional 364 shares in the last quarter. Huntington National Bank lifted its position in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock valued at $30,000 after purchasing an additional 645 shares in the last quarter. Finally, Spire Wealth Management bought a new position in shares of Bruker during the second quarter valued at about $32,000. 79.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Frank H. Laukien acquired 2,608 shares of the stock in a transaction dated Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This represents a 0.01% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 27.30% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.